Andrew Sassine - Gemphire Therapeutics Independent Director

Director

Mr. Andrew Sassine is an Independent Director of the Company. Mr. Sassine served in various positions at Fidelity Investments from 1999 to 2012, including as a Portfolio Manager for various funds from 2005 to December 2011. Mr. Sassine has also served on several boards of life science companies. Mr. Sassine currently serves on the board of directors of iCAD, Inc., a public cancer detection and radiation therapy solutions company and previously served on the boards of directors of FluoroPharma Medical, Inc., a public biopharmaceutical company, Acorn Energy, Inc., a public holding company focused on technology solutions for energy infrastructure asset management and CNS Response, Inc., a public psychiatric clinical decision support company. Mr. Sassine also serves on the board of directors of Freedom Meditech, Inc., a private medical device company, and Comhear Inc., a private digital audio software and device company, where he is also the chairman of the board of directors. Mr. Sassine serves on the Strategic Advisory Board of MD Revolution Inc., a private digital health service company. Mr. Sassine was a member of the Henry B. Tippie College of Business, University of Iowa Board of Advisors since 2009 and served on the board of trustees at the Clarke Schools for Hearing and Speech from 2009 through 2014 since 2015.
Age 54
Tenure 9 years
Professional MarksMBA
Phone734-245-1700
Webhttp://www.gemphire.com
Sassine holds a B.A. from the University of Iowa and an M.B.A. from the Wharton School at the University of Pennsylvania. Our Board believes Mr. Sassine should serve as a director based on his extensive experience in the public markets as well as his financial expertise.

Gemphire Therapeutics Management Efficiency

The company has return on total asset (ROA) of (44.9) % which means that it has lost $44.9 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (280.97) %, meaning that it created substantial loss on money invested by shareholders. Gemphire Therapeutics' management efficiency ratios could be used to measure how well Gemphire Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

DIRECTOR Age

Rodrigo KirbergCompania Cervecerias Unidas
54
Caroline TsayThe Coca Cola
39
Rate MargaretaVindicator Silver Lead Mining
37
Howard BuffettThe Coca Cola
60
Didier DebrosseCompania Cervecerias Unidas
59
Helene GayleThe Coca Cola
65
Robert KotickThe Coca Cola
57
Alexis HermanThe Coca Cola
73
Manuel EyzaguirreCompania Cervecerias Unidas
N/A
Cecil ConleeNational Beverage Corp
80
Alvaro RioCompania Cervecerias Unidas
N/A
Jose WesterflierCompania Cervecerias Unidas
56
Jose MackennaCompania Cervecerias Unidas
63
Philippe PasquetCompania Cervecerias Unidas
75
Richard DaleyThe Coca Cola
75
David WeinbergThe Coca Cola
69
Herbert AllenThe Coca Cola
53
Samuel HathornNational Beverage Corp
73
Ana OSheaThe Coca Cola
61
Christopher DavisThe Coca Cola
55
Rory CullinanCompania Cervecerias Unidas
60
Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease . The company was founded in 2008 and is headquartered in Livonia, Michigan. Gemphire Therapeutics operates under Biotechnology classification in USA and is traded on Nasdaq Capital Markets. It employs 7 people. Gemphire Therapeutics (GEMP) is traded on NASDAQ Exchange in USA and employs 7 people.

Management Performance

Gemphire Therapeutics Leadership Team

Elected by the shareholders, the Gemphire Therapeutics' board of directors comprises two types of representatives: Gemphire Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gemphire. The board's role is to monitor Gemphire Therapeutics' management team and ensure that shareholders' interests are well served. Gemphire Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gemphire Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Charles Bisgaier, Co-Founder, Chief Scientific Officer
Mina Sooch, President CEO
Kenneth Kousky, Independent Director
Andrew Sassine, Independent Director
Jeffrey Mathiesen, CFO
Seth Reno, Chief Commercial Officer
Pedro Lichtinger, Independent Director
Steven Gullans, Interim President Interim CEO, Director
David Lowenschuss, Co-Founder, Chief Legal Officer
Kent Hawryluk, Independent Director
Lee Golden, Chief Medical Officer

Gemphire Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gemphire Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Gemphire Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Gemphire Therapeutics' short interest history, or implied volatility extrapolated from Gemphire Therapeutics options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Other Consideration for investing in Gemphire Stock

If you are still planning to invest in Gemphire Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gemphire Therapeutics' history and understand the potential risks before investing.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Stocks Directory
Find actively traded stocks across global markets
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance